{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-053533","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.459014+00:00","generated_at":"2026-06-02T22:46:44.647077+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"FibroGen Q1 2024 revenue up 55% YoY to $55.9M; net loss narrows to $32.9M","bullets":["Net loss of $32.9M ($0.33 per share) vs $76.7M loss ($0.81 per share) in Q1 2023.","Roxadustat China net sales by FibroGen and JDE totaled $79.4M, up 24% YoY on 39% volume growth.","Topline data for pamrevlumab in metastatic pancreatic cancer expected mid-2024; LAPIS Phase 3 data in 3Q 2024.","Phase 1 FG-3246 (CD46 ADC) in mCRPC showed median rPFS of 8.7 months; 20% partial response rate.","Cash and receivables $214.7M; runway into 2026; FY 2024 roxadustat revenue guidance reaffirmed $120-135M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-053533","json":"https://secwatch.observer/filing/0000950170-24-053533.json","markdown":"https://secwatch.observer/filing/0000950170-24-053533.md","text":"https://secwatch.observer/filing/0000950170-24-053533.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000095017024053533/0000950170-24-053533-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000095017024053533/fgen-20240506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:46:44.647077+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}